Recurrent Gastroesophageal Junction Adenocarcinoma
4 clinical trials · Condition
◉ Watch Recurrent Gastroesophageal Junction Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT03918499) | City of Hope Medical Center | 2019-04-19 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (NCT03008278) | National Cancer Institute (NCI) | 2018-02-06 |
| MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C (NCT02391038) | Millennium Pharmaceuticals, Inc. | 2014-12-01 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (NCT01142388) | National Cancer Institute (NCI) | 2010-09-21 |
Track Recurrent Gastroesophageal Junction Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.